
Gilead Sciences (NASDAQ: GILD)
Gilead Sciences Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Gilead Sciences Company Info
Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.
News & Analysis
Top ETFs Tracking CRISPR Gene Editing
These exchange-traded funds track companies in this biotech space.
Why Gilead Sciences Stock Tumbled on Tuesday
Why Gilead Sciences Stock Slipped Today
Who Owns Google? History, Shareholders, & Facts
Why Gilead Sciences Stock Is Jumping Today
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
5 Best Dividend Mutual Funds
A closer look at some of the top dividend mutual funds for yield-seeking investors.
SPDR S&P Biotech ETF (XBI): How to Buy
Valuation
Podcast Episodes

What Happened With CAR-T Stocks in 2018
Here’s how CAR-T therapies did in their first full year on the market.

Should You Stick With Gilead Sciences?
Declining sales increase the stakes for Gilead's most-promising R&D projects.
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.

Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene's and Gilead Sciences’ Q2 2017 results are fueling gains in their stock prices, but is one of these stocks doing better than the other?
Earnings Transcripts
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2024.
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2024.
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2024.
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2024.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.